Use of Hydroxychloroquine and Chloroquine During the COVID-19 Pandemic: What Every Clinician Should Know

被引：152

作者：

Yazdany, Jinoos ^{[1
,3
]}

Kim, Alfred H. J. ^{[2
,4
]}

机构：

[1] Univ Calif San Francisco, Zuckerberg San Francisco Gen Hosp, San Francisco, CA 94143 USA

[2] Washington Univ, Sch Med, St Louis, MO 63110 USA

[3] Univ Calif San Francisco, Div Rheumatol, 1001 Potrero Ave,Bldg 30, San Francisco, CA 94110 USA

[4] Washington Univ, Sch Med, Div Rheumatol, Dept Med, 660 South Euclid Ave,Campus Box 8045, St Louis, MO 63110 USA

来源：

ANNALS OF INTERNAL MEDICINE | 2020年 / 172卷 / 11期

关键词：

D O I：

10.7326/M20-1334

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：754 / +

页数：3

共 10 条

[1]

Chen Jun, 2020, Zhejiang Da Xue Xue Bao Yi Xue Ban, V49, P215, DOI 10.3785/j.issn.1008-9292.2020.03.03

[2] Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus [J].

Costedoat-Chalumeau, Nathalie ;

Amoura, Zahir ;

Hulot, Jean-Sebastien ;

Abou Hammoud, Hala ;

Aymard, Guy ;

Cacoub, Patrice ;

Frances, Camille ;

Wechsler, Bertrand ;

Huong, Du Le Thi ;

Ghillani, Pascale ;

Musset, Lucile ;

Lechat, Philippe ;

Piette, Jean-Charles .

ARTHRITIS AND RHEUMATISM, 2006, 54 (10) :3284-3290

[3]

ESDAILE J, 1991, NEW ENGL J MED, V324, P150

[4]

Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI [10.1016/j.ijantimicag.2020.105949, 10.1016/j.ijantimicag.2020.106063]

[5] A Rush to Judgment? Rapid Reporting and Dissemination of Results and Its Consequences Regarding the Use of Hydroxychloroquine for COVID-19 [J].

Kim, Alfred H. J. ;

Sparks, Jeffrey A. ;

Liew, Jean W. ;

Putman, Michael S. ;

Berenbaum, Francis ;

Duarte-Garcia, Ali Prime ;

Graef, Elizabeth R. ;

Korsten, Peter ;

Sattui, Sebastian E. ;

Sirotich, Emily ;

Ugarte-Gil, Manuel F. ;

Webb, Kate ;

Grainger, Rebecca .

ANNALS OF INTERNAL MEDICINE, 2020, 172 (12) :819-+

[6] Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro [J].

Liu, Jia ;

Cao, Ruiyuan ;

Xu, Mingyue ;

Wang, Xi ;

Zhang, Huanyu ;

Hu, Hengrui ;

Li, Yufeng ;

Hu, Zhihong ;

Zhong, Wu ;

Wang, Manli .

CELL DISCOVERY, 2020, 6 (01)

[7] In vitro inhibition of human influenza A virus replication by chloroquine [J].

Ooi, Eng Eong ;

Chew, Janet Seok Wei ;

Loh, Jin Phang ;

Chua, Robert C. S. .

VIROLOGY JOURNAL, 2006, 3 (1)

[8] Chloroquine for influenza prevention: a randomised, double-blind, placebo controlled trial [J].

Paton, Nicholas I. ;

Lee, Lawrence ;

Xu, Ying ;

Ooi, Eng Eong ;

Cheung, Yin Bun ;

Archuleta, Sophia ;

Wong, Gerard ;

Wilder-Smith, Annelies .

LANCET INFECTIOUS DISEASES, 2011, 11 (09) :677-683

[9] Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology [J].

Schrezenmeier, Eva ;

Doerner, Thomas .

NATURE REVIEWS RHEUMATOLOGY, 2020, 16 (03) :155-166

[10] In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) [J].

Yao, Xueting ;

Ye, Fei ;

Zhang, Miao ;

Cui, Cheng ;

Huang, Baoying ;

Niu, Peihua ;

Liu, Xu ;

Zhao, Li ;

Dong, Erdan ;

Song, Chunli ;

Zhan, Siyan ;

Lu, Roujian ;

Li, Haiyan ;

Tan, Wenjie ;

Liu, Dongyang .

CLINICAL INFECTIOUS DISEASES, 2020, 71 (15) :732-739

← 1 →